Gossamer Bio to Present at Upcoming Investor Conferences

(NASDAQ:GOSS) SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Company will present at the following investor conferences in September. Cantor Global Healthcare Conference   Date / Time: September 3rd, at 9:10 AM ET Format: